Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)

Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply: * Participants who will receive artificial frozen-thawed embryo transfer (FET) cycle study interventions * Participants who have no more than two Day 5 embryos are planned to be transferred (follow the clinical practice of the study site) * Participants have received estradiol valerate for no more than 20 days * Participants have a transitional-endometrium of greater than or equal to 8 millimeter * Participants have normal uterine cavity * Participants can give signed informed consent * Participants are willing to follow the study protocol and able to complete the study Exclusion Criteria: * Participants are willing to follow the study protocol and able to complete the study * Participants with greater than or equal to three previously failed cycles of ET * Participants with diseases that cannot tolerate pregnancy * Hydrosalpinx * Severe endometriosis (Endometriosis American Society for Reproductive Medicine (ASRM) criteria from 1996) * Known hypersensitivity to progesterone, the excipients of Crinone and Duphaston Vaginal bleeding of unknown origin * History of recurrent miscarriages * Vaginitis * Thromboembolic diseases (thrombophlebitis, thromboembolic disorder, or cerebral apoplexy) or participants with a history of these conditions * Known or suspected progestogen-dependent neoplasm * Participation in another clinical trial within the past 30 days * Con…